New research reveals that individuals who come off new GLP-1 drugs like semaglutide or tirzepatide tend to recover reduced body mass much more quickly than those who halt traditional lifestyle regimens.
Published data in a prominent medical journal shows that while obese people can lose about a fifth of their body weight while undergoing treatment, the mass returns at an estimated rate of nearly a kilo each month after stopping.
"People buying these treatments need to be informed of the danger of quick rebound weight gain when the treatment ends," stated expert Dr. Susan Jebb.
That rate of regain means a return to starting mass within about 18 months.
Analyzing Treatments
The study, which reviewed dozens of studies involving over 9,000 of participants, compared the results of GLP-1 agonists with older methods.
Researchers note that individuals who lose weight through diet and exercise typically see a more gradual creep back—approximately 0.1 kg a month—once they finish.
The Reason for the Rapid Rebound
Nutrition scientists propose the way of the injections explains the heightened weight return.
GLP-1 drugs mimic a natural hormone called glucagon-like peptide-1, which helps regulate appetite.
"Long-term administration of the hormone concentrations far above than the body's typical production might result in the system to generate a reduced amount of its own natural GLP-1, and could lessen sensitivity to its effects," noted Dr. Adam Collins, a dietetics expert.
"Withdrawal of this GLP-1 'fix' leads to appetite is uncontrolled, making overeating a significant risk."
An Ongoing Disease?
The NHS advise the jabs for people with obesity-related medical conditions, alongside recommended lifestyle changes.
Many experts say that, considering the high risk of weight regain, the therapy should be considered long-term.
This view is reinforced by pharmaceutical companies, who note that the findings "underscore the long-term nature of obesity," similar to managing conditions like diabetes.
User Accounts
Users who have discontinued the jabs explain a sudden resurgence of cravings.
"I experienced something flipping and you become extremely hungry," recalled one woman.
The struggle is exacerbated if users have not developed permanent lifestyle or habit changes during therapy.
Growing Interest
Figures show that a significant number of adults in the UK have tried these injections in the last 12 months, with demand being substantial.
- Adoption is more common among women compared to males.
- The 40s and 50s age group shows the greatest usage rates.
- A large proportion obtain the medications through private prescriptions rather than public health services.
Ultimately, clinicians stress that while the jabs are effective agents for shedding pounds, they are not a permanent fix and maintained weight loss likely depends on ongoing lifestyle changes.
